Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance
- 1 July 2007
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 106 (1) , 75-81
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Prognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck CancersClinical Cancer Research, 2006
- The Expression of the Regulatory T Cell–Specific Forkhead Box Transcription Factor FoxP3 Is Associated with Poor Prognosis in Ovarian CancerClinical Cancer Research, 2005
- Leveraging the Activity of Tumor Vaccines with Cytotoxic ChemotherapyCancer Research, 2005
- A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphomaTransplantation and Cellular Therapy, 2005
- Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2003
- Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian CancerNew England Journal of Medicine, 2003
- Cancer Statistics, 2003CA: A Cancer Journal for Clinicians, 2003
- Cytokine-induced Killer Cells: NK-like T Cells with Cytotolytic Specificity against LeukemiaLeukemia & Lymphoma, 2003
- The Vascular Endothelial Growth Factor Receptor Kdr/Flk–1 Is A Major Regulator of Malignant Ascites Formation in the Mouse Hepatocellular Carcinoma ModelHepatology, 2001
- Second-Line Treatment of Ovarian CancerThe Oncologist, 2000